Koyfin Home > Directory > Health Care > Acorda Therapeutics > Gross Margin

Acorda Therapeutics Gross Margin Chart (ACOR)

Acorda Therapeutics annual/quarterly Gross Margin from 2010 to 2020. Gross margin is a company's total sales revenue minus its cost of goods sold (COGS), divided by total sales revenue, expressed as a percentage. The higher the percentage, the more the company retains on each dollar of sales, to service its other costs and debt obligations.
  • Acorda Therapeutics Gross Margin for the quarter ending June 06, 2020 was $80m a -3.83% decrease of -3m year over year
  • Acorda Therapeutics Gross Margin for the last 12 months ending June 06, 2020 was $83m a 7.70% increase of 6m year over year
  • Acorda Therapeutics Annual Gross Margin for 2019 was $82m a 3.17% increase of 3m from 2018
  • Acorda Therapeutics Annual Gross Margin for 2018 was $79m a -2.12% decrease of -2m from 2017
  • Acorda Therapeutics Annual Gross Margin for 2017 was $81m a 2.19% increase of 2m from 2016
Other Margins & Efficiency Metrics:
  • Acorda Therapeutics EBITDA Margin for the quarter ending December 12, 2018 was $-20m a 159.12% decrease of -32m year over year
  • Acorda Therapeutics Return on Capital % for the quarter ending December 12, 2018 was -4.27 a 144.67% decrease of -6.18 year over year
  • Acorda Therapeutics Return on Equity % for the quarter ending December 12, 2018 was 6.34 a 196.69% increase of 12.47 year over year
View Chart On Koyfin

Quarterly ACOR Gross Margin Data

06/2020$80m
03/2020$86m
12/2019$83m
09/2019$83m
06/2019$81m
03/2019$80m
12/2018$69m
09/2018$82m
06/2018$80m
03/2018$81m

Annual ACOR Gross Margin Data

2019$82m
2018$79m
2017$81m
2016$79m
2015$81m
2014$80m
2013$80m
2012$81m
2011$82m
2010$81m